Navigation Links
Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Women's Health and Drug Sector
Date:8/27/2012

BEVERLY HILLS, Calif., Aug. 27, 2012 /PRNewswire/ -- Pristine Solutions, Inc. (OTCQB: PRTN) (OTCBB: PRTN) ("Pristine Solutions" or the "Company") is pleased to announce that the Company has completed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions ("Eaton Scientific").

Eaton Scientific has identified, developed, and filed a patent for a novel indication of an existing FDA approved drug, homatropine, for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.  The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in the Los Angeles, California specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment. The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil. Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration. Homatropine has been prescribed continuously and safely in the United States for over 40 years.

"Every woman who has experienced hot flashes knows the devastating affects they have on themselves personally and on their loved ones.  Tropine 3 has been shown in individual cases to reduce the symptoms of hot flashes in terms of intensity, duration, and number of occurrences without the use of dangerous hormones which," said Michael Borkowski, CEO and President of Eaton Scientific Systems, Ltd. "We look forward to building market awareness and acceptance of Tropine 3 throughout the women's health care sector in hopes of improving the lives of the over 50 million women in America that would benefit from this proven safe and effective treatment for hot flashes."

The Company is currently assembling a senior management team and group of scientific advisors to assist in the ongoing development and clinical testing of Tropine 3.  Clinical trials currently being contemplated will be performed to strict FDA standards to provide support to claims made in Eaton Scientific's patent filed under USPTO #60/719,756.  Additional information regarding the near-term scheduling and commencement of planned Tropine 3 clinical trials will be made available in subsequent public statements.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Pristine Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Terso Solutions, Inc. with 2012 Best Practices Award
2. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
3. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
4. Manhattan Isotope Technology Completes Drug Master File With Food and Drug Administration
5. Manhattan Isotope Technology Completes Drug Master File With Federal Drug Administration
6. Regional Medical Center at Memphis Completes Rapid Six-Month Implementation of Comprehensive Perioperative and Anesthesia Solution from Surgical Information Systems
7. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
8. HeartWare Completes Acquisition Of World Heart Corporation
9. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
10. Hologic Completes Acquisition Of Gen-Probe
11. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... products, is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s ... health in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports ...
Breaking Medicine News(10 mins):